Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease

Fabry Disease (FD) is a rare, X-linked, lysosomal storage disease that mainly causes renal, cardiac and cerebral complications. Enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A is available, but approximately 50% of male patients with classical FD develop inhibiting anti-drug...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Veen, Sanne J., Vlietstra, Wytze J., van Dussen, Laura, van Kuilenburg, André B.P., Dijkgraaf, Marcel G. W., Lenders, Malte, Brand, Eva, Wanner, Christoph, Hughes, Derralynn, Elliott, Perry M., Hollak, Carla E. M., Langeveld, Mirjam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460974/
https://www.ncbi.nlm.nih.gov/pubmed/32806627
http://dx.doi.org/10.3390/ijms21165784

Ejemplares similares

Ejemplares similares